Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (SHA:600866)
China · Delayed Price · Currency is CNY 4.250
-0.210 (-4.71%)
Aug 21, 2026, 3:00 PM CST
SHA:600866 Revenue
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong had revenue of 4.45B CNY in the quarter ending June 30, 2026, with 7.98% growth. This brings the company's revenue in the last twelve months to 15.93B, down -6.34% year-over-year. In the year 2025, Star Lake Bioscience Co., Inc.Zhaoqing Guangdong had annual revenue of 15.90B, down -8.27%.
Revenue (ttm)
15.93B
Revenue Growth
-6.34%
P/S Ratio
0.44
Revenue / Employee
1.51M
Employees
10,528
Market Cap
7.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.90B | -1.43B | -8.27% |
| Dec 31, 2024 | 17.33B | -39.32M | -0.23% |
| Dec 31, 2023 | 17.37B | -112.59M | -0.64% |
| Dec 31, 2022 | 17.49B | 13.42B | 329.51% |
| Dec 31, 2021 | 4.07B | 2.95B | 264.72% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.84B |
| Aurisco Pharmaceutical | 1.68B |
| Chengdu Easton Biopharmaceuticals | 1.35B |
| Liaoning Chengda Biotechnology | 1.31B |
| Chengdu Kanghua Biological Products | 1.22B |
| Bio-Thera Solutions | 980.25M |
| Zhejiang Ausun Pharmaceutical | 794.80M |
| Daan Gene | 737.96M |